Development and Validation of the Nursing Home Minimum Data Set 3.0 Mortality Risk Score (MRS3)

被引:28
作者
Thomas, Kali S. [1 ,2 ]
Ogarek, Jessica A. [2 ]
Teno, Joan M. [3 ]
Gozalo, Pedro L. [1 ,2 ]
Mor, Vincent [1 ,2 ]
机构
[1] US Dept Vet Affairs, Med Ctr, Ctr Innovat Long Term Serv & Supports, Providence, RI USA
[2] Brown Univ, Sch Publ Hlth, Ctr Gerontol & Healthcare Res, Providence, RI 02912 USA
[3] Oregon Hlth & Sci Univ, Div Gen Internal Med & Geriatr, Portland, OR USA
来源
JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES | 2019年 / 74卷 / 02期
基金
美国国家卫生研究院;
关键词
Prognosis; Nursing home; Mortality; Risk adjustment; RANDOMIZED CONTROLLED-TRIALS; SURGICAL APGAR SCORE; COVARIATE ADJUSTMENT; PREDICT MORTALITY; RESIDENTS; INDEX; CANCER; PROGNOSIS; ADMISSION; INTERVIEW;
D O I
10.1093/gerona/gly044
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
Background To develop a score to predict mortality using the Minimum Data Set 3.0 (MDS 3.0) that can be readily calculated from items collected during nursing home (NH) residents' admission assessments. Participants We developed a training cohort of Medicare beneficiaries newly admitted to United States NHs during 2012 (N = 1,426,815) and a testing cohort from 2013 (N = 1,160,964). Methods Data came from the MDS 3.0 assessments linked to the Medicare Beneficiary Summary File. Using the training dataset, we developed a composite MDS 3.0 Mortality Risk Score (MRS3) consisting of 17 clinical items and patients' age groups based on their relation to 30-day mortality. We assessed the calibration and discrimination of the MRS3 in predicting 30- and 60-day mortality and compared its performance to the Charlson Comorbidity Index and the clinician's assessment of 6-month prognosis measured at admission. Results The 30- and 60-day mortality rates for the testing population were 2.8% and 5.6%, respectively. Results from logistic regression models suggest that the MRS3 performed well in predicting death within 30 and 60 days (C-Statistics of 0.744 [95% confidence limit (CL) = 0.741, 0.747] and 0.709 [95% CL = 0.706, 0.711], respectively). The MRS3 was a superior predictor of mortality compared to the Charlson Comorbidity Index (C-statistics of 0.611 [95% CL = 0.607, 0.615] and 0.608 [95% CL = 0.605, 0.610]) and the clinicians' assessments of patients' 6-month prognoses (C-statistics of 0.543 [95% CL = 0.542, 0.545] and 0.528 [95% CL = 0.527, 0.529]). Conclusions The MRS3 is a good predictor of mortality and can be useful in guiding decision-making, informing plans of care, and adjusting for patients' risk of mortality.
引用
收藏
页码:219 / 225
页数:7
相关论文
共 44 条
[1]  
Abicht-Swensen L M, 1999, Am J Hosp Palliat Care, V16, P527, DOI 10.1177/104990919901600308
[2]  
[Anonymous], 2012, RISK ADJUSTMENT MEAS
[3]   The TIMI risk score for unstable angina/non-ST elevation MI - A method for prognostication and therapeutic decision making [J].
Antman, EM ;
Cohen, M ;
Bernink, PJLM ;
McCabe, CH ;
Horacek, T ;
Papuchis, G ;
Mautner, B ;
Corbalan, R ;
Radley, D ;
Braunwald, E .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 284 (07) :835-842
[4]  
Brink Peter, 2015, Palliat Care, V9, P1, DOI 10.4137/PCRT.S20347
[5]  
Centers for Medicare & Medicaid Services, 2017, MDS 3 0 RAI MAN
[6]   Mortality-related factors and 1-year survival in nursing home residents [J].
Flacker, JM ;
Kiely, DK .
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2003, 51 (02) :213-221
[7]   Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE) [J].
Fox, Keith A. A. ;
Dabbous, Omar H. ;
Goldberg, Robert J. ;
Pieper, Karen S. ;
Eagle, Kim A. ;
Van de Werf, Frans ;
Avezum, Alvaro ;
Goodman, Shaun G. ;
Flather, Marcus D. ;
Anderson, Frederick A., Jr. ;
Granger, Christopher B. .
BMJ-BRITISH MEDICAL JOURNAL, 2006, 333 (7578) :1091-1094
[8]   An Apgar score for surgery [J].
Gawande, Atul A. ;
Kwaan, Mary R. ;
Regenbogen, Scott E. ;
Lipsitz, Stuart A. ;
Zinner, Michael J. .
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2007, 204 (02) :201-208
[9]   Randomized controlled trials with time-to-event outcomes:: How much does prespecified covariate adjustment increase power? [J].
Hernández, AV ;
Eijkemans, MJC ;
Steyerberg, EW .
ANNALS OF EPIDEMIOLOGY, 2006, 16 (01) :41-48
[10]   Covariate adjustment in randomized controlled trials with dichotomous outcomes increases statistical power and reduces sample size requirements [J].
Hernández, AV ;
Steyerberg, EW ;
Habbema, JDF .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 2004, 57 (05) :454-460